Teal Health provides an FDA‑authorized at‑home cervical cancer screening kit called the Teal Wand, which lets users collect a vaginal sample for high‑risk HPV testing without a speculum exam. After a brief telehealth visit to obtain a prescription, the kit is mailed, the sample is processed with the same Roche cobas® HPV assay used in clinics, and results are delivered via a secure portal, with virtual provider support for any needed follow‑up.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
5O+2Founders
Product
Problem
Many individuals who need cervical cancer screening avoid or delay testing because clinic-based Pap smears require a speculum exam that can be painful, uncomfortable, and inaccessible for those with limited mobility or who experience gender dysphoria. This results in a large screening gap, with about 25% of eligible people behind on recommended testing.
Solution
Teal Health offers the FDA‑authorized Teal Wand, a at‑home self‑collection device that enables users to obtain a vaginal sample for high‑risk HPV testing without a speculum. After a brief telehealth visit to obtain a prescription, a kit is mailed to the user, who collects the sample and returns it to a central lab where the same Roche cobas® HPV assay used in clinics is performed. Results are delivered securely through an online portal, and if follow‑up care is needed, a Teal provider coordinates virtual consultation and referrals. Clinical trials demonstrate 96% detection of cervical precancer and 95% positive percent agreement with clinician‑collected samples, matching standard accuracy while providing a comfortable, private experience. The service is compatible with major insurance plans, HSA/FSA payments, and offers a cash‑pay option.
Target Audience
Primary users are individuals aged 25–65 with a cervix who seek a comfortable, private alternative to clinic‑based Pap smears, including those who have experienced discomfort, access barriers, or gender dysphoria. The service also serves telehealth providers and health plans looking to expand cervical cancer screening coverage.
Features
- FDA‑authorized at‑home self‑collection device (Teal Wand) with patented design for easy vaginal sampling
- Uses the same FDA‑cleared Roche cobas® high‑risk HPV assay as in‑clinic Pap smears, ensuring clinical equivalence
- Integrated telehealth workflow: virtual prescription visit, kit mailing, and result delivery via secure portal
- Virtual provider support for result interpretation and coordination of follow‑up referrals
- Coverage through major insurers, HSA/FSA eligibility, and cash‑pay option; nationwide shipping across all 50 states
- Demonstrated 96% detection of cervical precancer and 95% positive percent agreement in a 600‑plus participant clinical trial